REG - Polarean Imaging PLC - Total Voting Rights

Polarean ImagingAnnouncement

30/10/2020 07:01

RNS Number : 6761D
  
Polarean Imaging PLC
  
30 October 2020
  
 

 
Polarean Imaging Plc 
("Polarean" or the "Company")  
  
Total Voting Rights 
  
Polarean Imaging plc (AIM: POLX), the medical ‑ imaging technology company, with a proprietary drug ‑ device combination product for the magnetic resonance imaging (MRI) market, announces that the total number of shares in issue and total voting rights as at the date of this announcement is 161,894,135 ordinary shares of £0.00037 each. 
 
The total issued share capital of the Company consists of 161,894,135 Ordinary Shares. This number may be used by Shareholders as the denominator for the calculation by which they will determine if they are required to notify their interest in, or change to their interest in, the Company under the FCA's Disclosure Guidance and Transparency Rules. 
  
Enquiries:   



Polarean Imaging plc


www.polarean.com / www.polarean-ir.com




Richard Hullihen, Chief Executive Officer


Via Walbrook PR




Jonathan Allis, Chairman


















SP Angel Corporate Finance LLP


Tel: +44 (0)20 3470 0470 




David Hignell / Soltan Tagiev (Corporate Finance)








Vadim Alexandre / Rob Rees (Corporate Broking)


















Walbrook PR


Tel: +44 (0)20 7933 8780 or polarean@walbrookpr.com




Paul McManus / Anna Dunphy


Mob: +44 (0)7980 541 893 / +44 (0)7879 741 001










 
About Polarean (www.polarean.com)
 
The Company and its wholly owned subsidiary, Polarean, Inc. (together the "Group") are revenue generating, medical drug-device combination companies operating in the high resolution functional magnetic resonance imaging market.
  
The Group develops equipment that enables existing MRI systems to achieve an improved level of pulmonary function imaging and specialises in the use of hyperpolarised Xenon gas (129Xe) as an imaging agent to visualise ventilation and gas exchange regionally in the smallest airways of the lungs, the tissue barrier between the lung and the bloodstream and in the pulmonary vasculature. Xenon gas exhibits solubility and signal properties that enable it to be imaged within other tissues and organs.
 
The Group operates in an area of significant unmet medical need and the Group's technology provides a novel diagnostic approach, offering a non-invasive and radiation-free functional imaging platform which is more accurate and less harmful to the patient than current methods. The annual burden of pulmonary disease in the US is estimated to be over US$150 billion.
The Group also develops and manufactures high performance MRI radiofrequency (RF) coils which are a required component for imaging 129Xe in the MRI system. The development of these coils by the Group facilitates the adoption of the Xenon technology by providing application-specific RF coils which optimise the imaging of 129Xe in MRI equipment for use as a medical diagnostic as well as a method of monitoring the efficacy of therapeutic intervention.
 
 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
  END
 
 
TVREAKENASEEFFA